The UK has some of the best patient data available anywhere in the world, and a preeminent position in the collection of cancer data at both an individual tumour and patient level.
Drug development can be quite a risky business at the best of times, but particularly in the biotech sector where companies may only have a few assets to their name.
Pharma giant UCB is to invest around £1 billion in the UK as part of a second life sciences sector deal with the UK government, with industry names such as Roche and IQVIA also committing t
Overview
Now more than ever before, biotech is the engine for innovation in medicine, finding, creating and delivering ground-breaking treatments to patients.